Biotechnology Archives - Page 30 of 31

Tuesday Dec 22, 2020 - 2:42 pm

InvestorNewsBreaks – Imagin Medical Inc. (CSE: IME) (OTCQB: IMEXF) Takes Game-Changing Visualization Method to the Next Level

Imagin Medical (CSE: IME) (OTCQB: IMEXF), a surgical imaging company, is at the forefront of change in its focus to establish a new standard of care in visualizing cancer. Minimally invasive surgery (“MIS”) using white light to illuminate tumor growth is the current standard of care for bladder cancer. This method is highly effective for visualizing cancerous tumors that protrude above the bladder’s wall. However,…

Tuesday Dec 22, 2020 - 2:29 pm

InvestorNewsBreaks – AzurRx BioPharma Inc. (NASDAQ: AZRX) Aims to Identify Best Delivery Method for Lead Drug Candidate

AzurRx BioPharma (NASDAQ: AZRX), a clinical-stage biopharmaceutical company specializing in the development of non-systemic, recombinant therapies for gastrointestinal diseases, recently submitted a protocol amendment request to the U.S. Food and Drug Administration (“FDA”). Approval of the amendment will allow AzurRx to modify its current Phase 2b OPTION 2 trial of MS1819 in cystic fibrosis (“CF”) patients to add a study arm that uses immediate release…

Tuesday Dec 22, 2020 - 1:22 pm

InvestorNewsBreaks – TPT Global Tech Inc. (TPTW) Announces Launch of ‘QuikLAB’ and ‘QuikPASS’ Apps

TPT Global Tech (OTC: TPTW), a provider of telecommunications, medical technology, media content for domestic and international syndication as well as technology solutions, today announced the release of two new products and services for use at its TPT Med Tech division. These include its "QuikLAB" App, designed for use in monitoring patient testing and vaccination history, and its "QuikPASS" Mobile App. QuikPASS is designed to…

Tuesday Dec 22, 2020 - 12:28 pm

InvestorNewsBreaks – Genprex Inc. (NASDAQ: GNPX) Reaches Another Significant Milestone with Scaled-up Production of Clinical-Grade REQORSA(TM)

Genprex (NASDAQ: GNPX), focused on developing life-changing therapies for patients with cancer and diabetes, has announced its completion of the manufacturing scale-up of REQORSA(TM) immunogene therapy. Subject to satisfactory completion of final testing currently underway, the clinical-grade production is intended to supply Genprex’s upcoming Acclaim-1 and Acclaim-2 clinical trials for the treatment of non-small cell lung cancer. The company recently announced the successful manufacturing technology…

Tuesday Dec 22, 2020 - 11:13 am

InvestorNewsBreaks – Brain Scientific Inc. (BRSF) CEO Talks Benefits of Disposable Brain Diagnostic Tools

Brain Scientific (OTCQB: BRSF) co-founder and CEO Boris Goldstein penned a recent article for “Healthcare” magazine. Titled “Brain Scientific: Neurology’s need for disposable solutions,” the article provides an overview of the need for new devices in the neurology market and the advantages of disposable brain diagnostic tools. Goldstein noted that his interest in brain diagnostic tools began when he was studying at college, where he used…

Tuesday Dec 22, 2020 - 10:30 am

InvestorNewsBreaks – DarioHealth Corp. (NASDAQ: DRIO) Finalizes Agreement to Provide RPM Solution to Presbyterian Medical Services

DarioHealth (NASDAQ: DRIO), a pioneer in the global digital therapeutics market, has inked an agreement with one of the largest integrated healthcare systems in the state of New Mexico to provide remote patient monitoring (“RPM”). The partnership with Presbyterian Medical Services begins Jan. 1, 2021. The agreement, which followed a rigorous request for proposal (“RFP”) process, reflects DRIO’s shift in focus to B2B2C and outlines the company’s…

Friday Dec 18, 2020 - 2:26 pm

InvestorNewsBreaks – Why Imagin Medical Inc. (CSE: IME) (OTCQB: IMEXF) Is ‘One to Watch’

Imagin Medical (CSE: IME) (OTCQB: IMEXF) is a surgical imaging company that is focused on establishing a new standard of care in visualizing cancer. The company’s initial focus is on bladder cancer and its first product is the i/Blue Imaging(TM) System. Based on advanced optics, light sensors and employing patented ultrasensitive imaging technology, Imagin believes its system can significantly improve surgeons’ ability to visualize and…

Friday Dec 18, 2020 - 1:33 pm

InvestorNewsBreaks – Tryp Therapeutics Inc. (CSE: TRYP) Marks Significant Milestone with Commencement of CSE Trading

Tryp Therapeutics (CSE: TRYP) today announced that its common shares have commenced trading on the Canadian Securities Exchange ("CSE") under the symbol "TRYP" effective Dec. 18, 2020. "Trading on the CSE is a significant milestone in Tryp's mission to transform the treatment of neuropsychiatric diseases with safe and effective psychedelic medicines," said Tryp CEO James Kuo, MD. "All of the drugs within our portfolio have…

Friday Dec 18, 2020 - 1:12 pm

InvestorNewsBreaks – Predictive Oncology Inc. (NASDAQ: POAI) Shines Spotlight on Innovative Media in Exclusive Interview

Predictive Oncology (NASDAQ: POAI), a knowledge-driven precision medicine company focused on applying data and artificial intelligence (“AI”) to personalized medicine and drug discovery, was recently featured in an exclusive audio interview with NetworkNewsWire. During the interview, POAI CEO Carl Schwartz noted recent milestones, outlined strategic goals and provided key updates on the company’s four impressive subsidiaries: Skyline Medical, TumorGenesis, Soluble Biotech and Helomics. Schwartz indicated…

Friday Dec 18, 2020 - 8:30 am

InvestorNewsBreaks – CNS Pharmaceuticals Inc. (NASDAQ: CNSP) Hosts Conference Call to Discuss IND Approval, Phase 2 Berubicin Trial

CNS Pharmaceuticals (NASDAQ: CNSP), a biopharmaceutical company specializing in the development of novel treatments for primary and metastatic cancers of the brain and central nervous system, on Thursday announced that it will be holding a conference call to discuss its recently approved Investigational New Drug (“IND”) application involving its lead product candidate Berubicin for the treatment of Glioblastoma Multiforme (“GBM”). The company also intends to discuss…

Thursday Dec 17, 2020 - 12:18 pm

InvestorNewsBreaks – Brain Scientific Inc. (BRSF) Announces NeuroCap for Children, Enters Pediatric Market

Brain Scientific (OTCQB: BRSF), a neurology-focused medical device and software company, has launched its next-generation, disposable EEG cap, NeuroCap(TM) in a children’s size, making the innovative product available for use in the U.S. pediatric market. The smaller NeuroCap headset is designed to overcome common challenges that arise when conducting an electroencephalogram (“EEG”), such as measuring and marking the patient’s head, and following sanitation protocols. The pediatric…

Thursday Dec 17, 2020 - 10:46 am

InvestorNewsBreaks – LexaGene Holdings Inc. (TSX.V: LXG) (OTCQB: LXXGF) Proprietary Systems to be Utilized at Leading Specialty, Emergency Veterinary Care Hospitals

LexaGene Holdings (TSX.V: LXG) (OTCQB: LXXGF), a molecular diagnostics company that develops fully automated rapid pathogen detection systems, has finalized agreements to place its exclusive MiQLab(TM) systems at two specialty and emergency veterinary hospitals as part of the company’s Early Access Program (“EAP”); the company anticipates placing the systems in early 2021. The two practices are Veterinary Specialty Hospital (“VSH”) of Palm Beach Gardens, Florida, and Denver…

Thursday Dec 17, 2020 - 9:18 am

InvestorNewsBreaks – CNS Pharmaceuticals Inc. (NASDAQ: CNSP) Secures FDA Approval of IND Application for Brain Cancer Drug Candidate Berubicin

CNS Pharmaceuticals (NASDAQ: CNSP), a biopharmaceutical company specializing in the development of novel treatments for primary and metastatic cancers of the brain and central nervous system, this morning announced that it has received US Food and Drug Administration (“FDA”) approval of its Investigational New Drug (“IND”) application on its lead product candidate Berubicin for the treatment of Glioblastoma Multiforme (“GBM”). This approval signifies a crucial step…

Wednesday Dec 16, 2020 - 8:30 am

InvestorNewsBreaks – Vivos Therapeutics Inc. (NASDAQ: VVOS) Closes IPO, Exercises Option to Purchase Additional Shares

Vivos Therapeutics (NASDAQ: VVOS), a medical technology company focused on developing and commercializing innovative treatments for patients suffering from sleep disordered breathing, including obstructive sleep apnea, has announced the closing of its initial public offering (“IPO”). The IPO consisted of a total of 4,025,000 shares — 3,500,000 shares of common stock combined with 525,000 additional shares made available through the exercise of the underwriters’ option to…

Tuesday Dec 15, 2020 - 2:38 pm

InvestorNewsBreaks – Way2Grow (‘W2G’) Biopharma Company Announces Entry into Cannabis Productivity, Plans for Psychedelic Research and Development

Way2Grow Nurseries (“Way2Grow” or “W2G”), a privately held biopharma company, today announced its entry into the productivity phase of cannabis cultivation, micropropagation and extraction. The company also announced its preparation of a Health Canada application towards psychedelic research and development for a medicinal mushroom (Psilocybe semilanceata) Dealer Licence and a Section 56 Exemption for use of psilocybin production and extraction for planned preclinical research under…

Tuesday Dec 15, 2020 - 11:20 am

InvestorNewsBreaks – LexaGene (TSX.V: LXG) (OTCQB: LXXGF) Announces PO from Ethos Discovery for Proprietary MiQLab

LexaGene Holdings (TSX.V: LXG) (OTCQB: LXXGF), a molecular diagnostics company that develops fully automated rapid pathogen detection systems, received a purchase order (“PO”) from Ethos Discovery for its exclusive MiQLab(TM). Designed for use in veterinary hospitals, MiQLab features an automated, easy-to-use system and rapid, in-hospital identification of pathogens. That information is invaluable for veterinarians as they make patient-care decisions. LexaGene’s MiQLab tests samples using real-time PCR, which…

Monday Dec 14, 2020 - 10:53 am

InvestorNewsBreaks – MustGrow Biologics Corp. (CSE: MGRO) (OTCQB: MGROF) (FRA: 0C0) Announces Strategic Board Appointment

MustGrow (CSE: MGRO) (OTCQB: MGROF) (FRA: 0C0), an agriculture biotech company focused on providing natural biological protection for high value crops, today announced the appointment of David M. Borecky, vice president and chief accounting officer of Impossible Foods, to its board of directors. According to the update, David will leverage his extensive global relationships in the plant-based innovation community to accelerate and raise awareness of…

Friday Dec 11, 2020 - 2:45 pm

InvestorNewsBreaks – Brain Scientific Inc. (BRSF) Engages Dalmore Group for Expert Strategic Advice, Innovative Solutions

Brain Scientific (OTCQB: BRSF), a commercial-stage health-care company focused on developing innovative and proprietary medical devices and software, recently entered into a strategic partnership with the Dalmore Group. A member of FINRA and SIPC, the Dalmore Group maintains an active presence in the Regulation A+ equity funding space. The company is one of the world’s most active broker-dealers and has served on more than 50…

Friday Dec 11, 2020 - 2:35 pm

InvestorNewsBreaks – AzurRx BioPharma Inc. (NASDAQ: AZRX) Advancing MS1819 in Fight to Improve Treatment of EPI in CF, CP Patients

AzurRx BioPharma (NASDAQ: AZRX) is focused on the development of its lead drug candidate, MS1819, for exocrine pancreatic insufficiency (“EPI”) in patients suffering from cystic fibrosis (“CF”) and chronic pancreatitis (“CP”). While CF is a relatively rare genetic disease, innovative and effective therapies are needed. CF is a dangerous condition that affects multiple body functions and organs, putting patients at risk of developing severe life-threatening…

Thursday Dec 10, 2020 - 10:42 am

InvestorNewsBreaks – VistaGen Therapeutics Inc. (NASDAQ: VTGN) Granted Patent for Innovative Treatment for MDD

VistaGen Therapeutics (NASDAQ: VTGN), a biopharmaceutical company developing new-generation medicines with the potential to go beyond the current standard of care for anxiety, depression and other central nervous system (“CNS”) disorders, has been granted a patent by the Korean Intellectual Property Office (“KIPO”) for one of its treatments for depression. VistaGen received notification that KIPO has issued a decision to grant Patent Application No. 10-2015-7020176.…

Thursday Dec 10, 2020 - 9:49 am

InvestorNewsBreaks – Processa Pharmaceuticals Inc. (NASDAQ: PCSA) Featured in Research Report

Processa Pharmaceuticals (NASDAQ: PCSA), a clinical-stage biopharmaceutical company developing products to improve the survival and/or quality of life for patients who have unmet medical needs, was featured in a research report by the Benchmark Company LLC. The report, titled “Processa Pharmaceuticals Inc. (PCSA) Processing Assets to the FDA; Initiate at Buy,” lists a $15 price target at initiation of coverage. The report reads, “We initiate…

Wednesday Dec 09, 2020 - 1:41 pm

InvestorNewsBreaks – Predictive Oncology Inc. (NASDAQ: POAI) Issues Shareholder Letter Regarding Special Meeting

Predictive Oncology (NASDAQ: POAI), a knowledge-driven company focused on applying artificial intelligence (“AI”) to personalized medicine and drug discovery, today sent a letter to shareholders regarding its virtual special meeting of stockholders, originally scheduled for Dec. 1, 2020, which will be reconvened to 3 p.m. CST on Dec. 30, 2020. According to the update, POAI’s board of directors and management urge all shareholders to vote…

Tuesday Dec 08, 2020 - 2:16 pm

InvestorNewsBreaks – CNS Pharmaceuticals Inc. (NASDAQ: CNSP) Shines Spotlight on Clinical Design for Upcoming Phase 2 Trial

CNS Pharmaceuticals (NASDAQ: CNSP), a biopharmaceutical company specializing in the development of novel treatments for primary and metastatic cancers of the brain and central nervous system, is advancing a drug candidate it hopes will beat the deadly brain cancer Glioblastoma Multiforme (“GBM”). The company recently announced that its submission of an Investigational New Drug (“IND”) application to the U.S. Food & Drug Administration (“FDA”) has…

Tuesday Dec 08, 2020 - 1:59 pm

InvestorNewsBreaks – Predictive Oncology Inc.’s (NASDAQ: POAI) Soluble Biotech Solution Shaves Time, Money to Optimize Therapeutic Formulations

Predictive Oncology (NASDAQ: POAI) is a knowledge-driven precision medicine company focused on applying data and artificial intelligence (“AI”) to personalized medicine and drug discovery. Through its subsidiary Soluble Biotech, the company delivers a solution that reduces the cost, time and manpower needed to optimize therapeutic formulations. A recent article discussing this reads, “HSC Technology is a self-contained, automated system that conducts high-throughput, self-interaction chromatography screens,…

Monday Dec 07, 2020 - 10:10 am

InvestorNewsBreaks – MustGrow Biologics Corp. (CSE: MGRO) (OTCQB: MGROF) (FRA: 0C0) Announces Upcoming Investor Webcast

MustGrow (CSE: MGRO) (OTCQB: MGROF) (FRA: 0C0), an agriculture biotech company focused on providing natural biological crop protection for high value crops, today announced an upcoming live webcast for its investment community. According to the update, MustGrow is poised to capitalize in 2021 and beyond in a rapidly growing market as regulatory framework moves to favor organic biopesticides and bioherbicides. The webcast is scheduled to…

Thursday Dec 03, 2020 - 3:25 pm

InvestorNewsBreaks – 180 Life Sciences Corp. (NASDAQ: ATNF) to Present at LD Micro Main Event

180 Life Sciences (NASDAQ: ATNF, ATNFW), a clinical-stage biotechnology company with its lead indication in phase 2b/3, focused on the development of novel drugs that fulfill unmet needs in inflammatory diseases, fibrosis and pain, today announced that it will participate in the LD Micro Virtual Main Event 2020 Conference. According to the update, 180 Life Sciences CEO Dr. James Woody is scheduled to present at…

Wednesday Dec 02, 2020 - 11:16 am

InvestorNewsBreaks – Brain Scientific Inc. (BRSF) Files Patent Application for Flexible EEG Cap

Brain Scientific (OTCQB: BRSF), a neurology-focused medical device and software company, has filed a provisional patent application in the United States Patent and Trademark Office (“USPTO”) entitled, “FULL HEAD APPARATUS AND ELECTRODES FOR CONDUCTING ELECTROENCEPHALOGRAPHY.” “The new EEG product for which Brain Scientific is seeking a patent approval is a flexible head cap for conducting electroencephalography,” said BRSF Marketing Director Irina Nazarova. “The cap carries…

Tuesday Dec 01, 2020 - 1:19 pm

InvestorNewsBreaks — MustGrow Biologics Corp. (CSE: MGRO) (OTCQB: MGROF) (FRA: 0C0) Releases Test Results for Control of Threat to $25 Billion Banana Industry

MustGrow Biologics (CSE: MGRO) (OTCQB: MGROF) (FRA: 0C0) has announced initial test results of its mustard-derived organic biopesticide formulation designed to control Fusarium wilt TR4, a destructive pathogen threatening the global banana industry, which is valued at $25 billion. Completed via third-party independent laboratory CyberAgrot SAS in Colombia, the testing reported 100% control Fusarium wilt TR4, known as Panama disease. The disease led to the declaration of…

Monday Nov 30, 2020 - 3:25 pm

InvestorNewsBreaks – Brain Scientific Inc. (BRSF) Enters Strategic Agreement for Expansion into EU Market

Brain Scientific’s (OTCQB: BRSF) Vice President of Marketing, Stuart Bernstein, has written an article for Health Care Business News titled, “COVID's influence on neurology drives need for disposable technologies.” The piece discusses increased concern for health care and frontline workers treating emergent cases for COVID-19 patients developing neurological symptoms and conditions, as well as a critical need for testing solutions. The article reads, “Sudden onset…

Monday Nov 30, 2020 - 11:00 am

InvestorNewsBreaks – AzurRx BioPharma Inc. (NASDAQ: AZRX) Announces Advancement of MS1819 Combination Therapy Trial in Turkey

AzurRx BioPharma (NASDAQ: AZRX), a company specializing in the development of non-systemic, recombinant therapies for gastrointestinal diseases, today announced that the first two patients have been dosed in Turkey for its Phase 2 trial. The trial evaluates its investigational drug, MS1819, in combination with the current standard of care, porcine-derived pancreatic enzyme replacement therapy (“PERT”), for the treatment of severe exocrine pancreatic insufficiency (“EPI”) in patients…

Wednesday Nov 25, 2020 - 3:14 pm

InvestorNewsBreaks – Why Brain Scientific Inc. (BRSF) Is ‘One to Watch’

Brain Scientific (OTCQB: BRSF) is a commercial-stage health care company focused on developing innovative and proprietary medical devices and software. The company’s mission is to modernize brain diagnostics by employing leading-edge technologies to bridge the widening gap in access to quality care. A recent article discussing the company reads, “Brain Scientific’s first phase of development, from 2018 to 2019, saw the inception of portable, clinical-grade,…

Wednesday Nov 25, 2020 - 2:44 pm

InvestorNewsBreaks – Trxade Group Inc.’s (NASDAQ: MEDS) Platform Meets Today’s Demands Through Intelligent Design

Trxade Group NASDAQ: MEDS), an integrated drug-procurement, delivery and health care platform, is ideally situated as the global pandemic has led to a cascade of changes involving how health care is administered, perhaps most notably in the increased adoption of telehealth services. Trxade Group’s business model appears to aptly and effectively meet today’s demands, largely demonstrated by the company’s revenue growth that has far exceeded…

Wednesday Nov 25, 2020 - 12:28 pm

InvestorNewsBreaks – DarioHealth Corp. (NASDAQ: DRIO) to Provide Digital Therapeutics Solution to Employees of Fortune 500 Company

DarioHealth (NASDAQ: DRIO), a pioneer in the global digital therapeutics market, will be providing its digital therapeutics solution to qualified employees of a U.S.-based Fortune 500 technology company. The contract, which goes into effect on Jan. 1, 2021, with the beginning of a new benefits year, calls for Dario to provide its digital diabetes tools and coaching to employees and their dependents. “We believe that…

Tuesday Nov 24, 2020 - 3:18 pm

InvestorNewsBreaks – 180 Life Sciences Corp. (NASDAQ: ATNF) to Ring Nasdaq Opening Bell

180 Life Sciences (NASDAQ: ATNF, ATNFW), a clinical-stage biotechnology company with its lead indication in phase 2b/3, focused on the development of novel drugs that fulfill unmet needs in inflammatory diseases, fibrosis and pain, today announced that, in celebration of its recently completed initial public offering, it will ring the Nasdaq Stock Exchange opening bell on November 27, 2020. 180 Life Sciences CEO Dr. James…

Tuesday Nov 24, 2020 - 2:46 pm

InvestorNewsBreaks – Processa Pharmaceuticals Inc. (NASDAQ: PCSA) Featured in Korea Biomedical Review Article

Processa Pharmaceuticals (NASDAQ: PCSA), a clinical-stage biopharmaceutical company developing products to improve the survival and/or quality of life for patients who have unmet medical needs, was featured in a recent article published in the Korea Biomedical Review. The piece, titled “Yuhan emerges as global new-drug developer with $3.6 billion tech export,” discusses Yuhan Corp.’s (OCT: YUHNF) move to enter technology transfer deals with global pharmaceutical…

Tuesday Nov 24, 2020 - 1:50 pm

InvestorNewsBreaks – AzurRx BioPharma Inc. (NASDAQ: AZRX) Featured in Stock2Me Podcast

AzurRx BioPharma (NASDAQ: AZRX), a company specializing in the development of non-systemic, recombinant therapies for gastrointestinal diseases, was featured in InvestorBrandNetwork’s (“IBN”) latest episode of its Stock2Me Podcast. Stock2Me Podcasts feature a fascinating array of companies and individuals, many of whom are revolutionizing business practices within their respective markets. AZRX president and CEO James Sapirstein joins IBN’s Stuart Smith in the latest episode to discuss how…

Tuesday Nov 24, 2020 - 1:23 pm

InvestorNewsBreaks – CNS Pharmaceuticals Inc. (NASDAQ: CNSP) CEO Discusses Brain Cancer Drug During Syndicated Broadcast

CNS Pharmaceuticals (NASDAQ: CNSP), a biopharmaceutical company specializing in the development of novel treatments for primary and metastatic cancers of the central nervous system, is featured in a recent NetworkNewsAudio (“NNA”) broadcast. During the broadcast, CNS Pharmaceuticals CEO John Climaco explains that the company has recently submitted an investigational new drug (“IND) application to the U.S. Food & Drug Administration (“FDA”) for its brain cancer…

Tuesday Nov 24, 2020 - 1:01 pm

InvestorNewsBreaks – Genprex Inc. (NASDAQ: GNPX) to Present at Diamond Equity Research Emerging Growth Invitational

Genprex (NASDAQ: GNPX), a clinical-stage gene therapy company focused on developing life-changing therapies for patients with cancer and diabetes, today announced that it will participate at the Diamond Equity Research Emerging Growth Invitational taking place virtually on Dec. 1, 2020. According to the update, Genprex’s executive vice president and COO, Michael Redman, will virtually deliver a company overview to investors followed by a guided question…

Tuesday Nov 24, 2020 - 10:45 am

InvestorNewsBreaks — MustGrow Biologics Corp. (CSE: MGRO) (OTCQB: MGROF) (FRA: 0C0) Outlines Investor Initiatives, Announces Conference Presentation

MustGrow Biologics (CSE: MGRO) (OTCQB: MGROF) (FRA: 0C0), an agricultural biotech company focused on developing and commercializing natural biological solutions for high-value crops, announced its upcoming investor awareness initiatives today. In addition, the company will be conducting a presentation today at the Future of Food Investment Conference; one-on-one investor meetings are also being scheduled for next week. According to the announcement, MustGrow’s key programs and…

Monday Nov 23, 2020 - 12:37 pm

InvestorNewsBreaks – 180 Life Sciences Corp. (NASDAQ: ATNF) Secures Additional Patents, Significantly Strengthening IP Portfolio

180 Life Sciences (NASDAQ: ATNF, ATNFW), a clinical-stage biotechnology company with its lead indication in phase 2b/3, focused on the development of novel drugs that fulfill unmet needs in inflammatory diseases, fibrosis and pain, today announced the continued expansion of its IP portfolio. According to the update, the company, on Nov. 20, 2020, received notice from the USPTO that it will publish application 62/722,263 “Method…

InvestorNewsBreaks

NewsBreak Category: Biotechnology

Get Started with InvestorWire

Press Distribution

Explore Press Distribution Solutions

Discover Add-on Solutions